Anjali Jain

Summary

Affiliation: Cedars-Sinai Medical Center
Country: USA

Publications

  1. pmc HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation
    Anjali Jain
    Sumner M Redstone Prostate Cancer Research Program, Cedars Sinai Medical Center, Los Angeles, California, USA
    Cancer Res 70:1989-99. 2010
  2. doi Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling
    Sheldon R Mink
    Louis Warschaw Prostate Cancer Center, Sumner M Redstone Prostate Cancer Research Program, Cedars Sinai Medical Center, Los Angeles, California, USA
    Prostate 70:1201-10. 2010
  3. pmc Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes
    Shannon M Mumenthaler
    Sumner M Redstone Prostate Cancer Research Program, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Mol Cancer Ther 8:2882-93. 2009
  4. ncbi 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth
    Noriyuki Takai
    Division of Hematology Oncology, Cedars Sinai Medical Center UCLA School of Medicine, Los Angeles, CA 90048, USA
    Cancer 104:2701-8. 2005
  5. pmc Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition
    Kian Kani
    University of Southern California, Los Angeles, CA 90033, USA
    Mol Cancer Ther 11:1071-81. 2012
  6. ncbi Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma
    Michael Hedvat
    Louis Warschaw Prostate Cancer Center, Cedars Sinai Medical Center, 8631 West Third Street, Suite 1001E, Los Angeles, CA 90048, USA
    Cancer Cell 5:565-74. 2004
  7. ncbi Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial
    Ronald L Shazer
    Louis Warschaw Prostate Cancer Center, Cedars Sinai Medical Center, 8631 West Third Street, Los Angeles, CA 90048, USA
    BJU Int 97:691-7. 2006
  8. ncbi PPARgamma signaling: one size fits all?
    Anjali Jain
    Louis Warschaw Prostate Cancer Center, Cedars Sinai Prostate Cancer Center, Los Angeles, California 90048, USA
    Cell Cycle 3:1352-4. 2004
  9. pmc Epithelial membrane protein-1 is a biomarker of gefitinib resistance
    Anjali Jain
    Louis Warschaw Prostate Cancer Center, Los Angeles, CA 90048, USA
    Proc Natl Acad Sci U S A 102:11858-63. 2005
  10. pmc Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs
    Sheldon R Mink
    Cedars Sinai Medical Center, 8700 Beverly Boulevard, Davis 6012, Los Angeles, CA 90048, USA
    Mol Cancer Res 8:809-20. 2010

Collaborators

Detail Information

Publications11

  1. pmc HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation
    Anjali Jain
    Sumner M Redstone Prostate Cancer Research Program, Cedars Sinai Medical Center, Los Angeles, California, USA
    Cancer Res 70:1989-99. 2010
    ..Furthermore, EGFR kinase inhibition induces HER kinase receptors to engage in alternative dimerization that can ultimately influence therapeutic selection and responsiveness...
  2. doi Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling
    Sheldon R Mink
    Louis Warschaw Prostate Cancer Center, Sumner M Redstone Prostate Cancer Research Program, Cedars Sinai Medical Center, Los Angeles, California, USA
    Prostate 70:1201-10. 2010
    ..In this study, we explore an interaction between beta2M expression, prostate cancer tissue, and the androgen signaling axis...
  3. pmc Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes
    Shannon M Mumenthaler
    Sumner M Redstone Prostate Cancer Research Program, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Mol Cancer Ther 8:2882-93. 2009
    ..These findings support the idea that inhibiting Pim kinases, in combination with a chemotherapeutic agent, could play an important role in prostate cancer treatment by targeting the clinical problem of chemoresistance...
  4. ncbi 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth
    Noriyuki Takai
    Division of Hematology Oncology, Cedars Sinai Medical Center UCLA School of Medicine, Los Angeles, CA 90048, USA
    Cancer 104:2701-8. 2005
    ..HER2 is a ligand-less member of the HER family that functions as the preferred coreceptor for epidermal growth factor receptor (EGFR), HER3, and HER4...
  5. pmc Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition
    Kian Kani
    University of Southern California, Los Angeles, CA 90033, USA
    Mol Cancer Ther 11:1071-81. 2012
    ..In doing so, we also were able to identify which proteins might be useful as markers for monitoring response and which proteins might be useful as markers for a priori prediction of response...
  6. ncbi Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma
    Michael Hedvat
    Louis Warschaw Prostate Cancer Center, Cedars Sinai Medical Center, 8631 West Third Street, Suite 1001E, Los Angeles, CA 90048, USA
    Cancer Cell 5:565-74. 2004
    ..This study introduces a novel concept of an in vivo crosstalk between the HER-kinase axis and PPARgamma pathways, ultimately leading to negative regulation of PPARgamma activity and tumor growth inhibition...
  7. ncbi Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial
    Ronald L Shazer
    Louis Warschaw Prostate Cancer Center, Cedars Sinai Medical Center, 8631 West Third Street, Los Angeles, CA 90048, USA
    BJU Int 97:691-7. 2006
    ....
  8. ncbi PPARgamma signaling: one size fits all?
    Anjali Jain
    Louis Warschaw Prostate Cancer Center, Cedars Sinai Prostate Cancer Center, Los Angeles, California 90048, USA
    Cell Cycle 3:1352-4. 2004
    ..Outcome of PPARgamma activation in cancer cells is not one-dimensional. PPARgamma signaling is dependent upon PPARgamma ligand affinity and binding characteristics, target cell context and interacting signaling networks...
  9. pmc Epithelial membrane protein-1 is a biomarker of gefitinib resistance
    Anjali Jain
    Louis Warschaw Prostate Cancer Center, Los Angeles, CA 90048, USA
    Proc Natl Acad Sci U S A 102:11858-63. 2005
    ..This report suggests the role of the adhesion molecule, EMP-1, as a biomarker of gefitinib clinical resistance, and further suggests a probable cross-talk between this molecule and the EGFR signaling pathway...
  10. pmc Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs
    Sheldon R Mink
    Cedars Sinai Medical Center, 8700 Beverly Boulevard, Davis 6012, Los Angeles, CA 90048, USA
    Mol Cancer Res 8:809-20. 2010
    ..This is the first demonstration that the tumor stroma is modified with acquisition of EGFR-TKI resistance and that it further contributes in promoting drug resistance...
  11. ncbi Identification of an androgen-dependent enhancer within the prostate stem cell antigen gene
    Anjali Jain
    Department of Urology, UCLA School of Medicine, Los Angeles, California 90095, USA
    Mol Endocrinol 16:2323-37. 2002
    ..The remainder of the enhancer contains elements that function synergistically with the AR. We discuss the structural organization of the PSCA enhancer and compare it with that found in other AR-regulated genes...

Research Grants1

  1. Functional Genomics Tools for HER2 heterodimers and Androgen Receptor Signaling
    Anjali Jain; Fiscal Year: 2007
    ..Androgen receptor is one such protein. Our research proposes to develop methods to search for compounds that specifically block the androgen receptor in prostate cancer cells. [unreadable]..